with a stent more than one week were significantly less likely to report pain in the hours after stent removal (OR: 0.59, 95% CI: 0.35-0.99). Female gender (OR: 2.41, 95% CI: 1.42-4.10) was associated with increased pain after stent removal, while increasing age was inversely associated (OR: 0.52, 95% CI: 0.36-0.74).
INTRODUCTION AND OBJECTIVES:
To properly use the Ureteric Symptom Score Questionnaire (USSQ) to evaluate, in a randomized control study, the effect of tamsulosin, solifenacin, and their combination in improving symptoms and quality of life in patients with indwelling ureteral stents.
METHODS: After institutional review board approval, 260 patients with a ureteral stent were randomly assigned to receive tamsulosin 0.4 mg, solifenacin 5 mg, or placebo and further randomized to receive their combination. The validated USSQ was completed 1 and 4 weeks after stent insertion and 4 weeks after stent removal. KruskalWallis test, chi-squared test (or Fisher's exact test), one-way analysis of variance, and T-test (or Wilcoxon rank-sum test if not normal data) were used for statistical analysis. The results were considered significant at p<0.05.
RESULTS: Patients receiving tamsulosin or solifenacin expressed significantly lower urinary (p<0.001), pain (p<0.001 with stent in situ), and general health index (p[0.002 in first and p<0.001 in fourth week with stent in situ) scores. Sexual life and quality of work were also positively influenced. Patients on combination therapy expressed lower urinary (p<0.001) and pain (p<0.001) scores in the fourth week with stent in situ and work performance in the first week and with stent in situ (p[0.001) and after stent removal (p[0.005). No patients had to discontinue medication due to side effects.
CONCLUSIONS: Stent-related morbidity is a reality in the majority of patients. Simple medication, such as tamsulosin and solifenacin alone or in combination, improves stent-related symptoms and has a positive impact on quality of life.
Source of Funding: NONE

PD12-10 SINGLE 24-HR URINE COLLECTION LEADS TO UNDER-DETECTION OF METABOLIC ABNORMALITIES WHEN COMPARED TO CONSECUTIVE COLLECTIONS IN PEDIATRIC STONE FORMERS
Michael Lam*, Casey Seideman, Solange Bassale, Aaron Bayne, Portland, OR INTRODUCTION AND OBJECTIVES: Metabolic evaluation of pediatric stone formers includes 24-hour urine collection and analysis. It is generally recommended 24-hour urine collection be performed after a single stone episode in children due to their predilection for identifiable metabolic abnormalities. Within the adult literature there is disagreement on the adequacy of a single collection, and some argue that two should be performed. Using a large multi-institutional database of pediatric stone formers, we evaluated this question in children and hypothesized that a single collection could lead to undertreatment of patients.
METHODS: All patients who had two consecutive 24-hr collections performed between 2007-2013 were included. Using established cutoffs in the literature, we determined whether values were classified as normal or abnormal. This included calcium > 4mgkg/day, oxalate > 40mg/1.73m2, citrate <310/1.73m2 in girls and <365/1.73m2 in boys, uric acid >0.815 g/1.73m2, calcium phosphate > 2, SS calcium oxalate > 12, and pH < 5.5 or > 6.2. We classified those with two normal or abnormal collections as concordant, and those with two conflicting collections as discordant.
RESULTS: A total of 51 patients underwent two consecutive 24-hr urine collections. Discordance among collections ranged as high as 29.41% (15 children). Urinary calcium was discordant among 14 children (27.45%, Figure) . Of those with initial normal collections, we calculated those with abnormal second collections. 27.03% had abnormal calcium values on their second collection despite a normal calcium values on their first collection. Other parameters were 5.13% for oxalate, 12.5% for citrate, 4.17% for uric acid, 17.07% for SS calcium oxalate, 36.36% for calcium phosphate, and 42.86% for pH.
CONCLUSIONS: There is a clinically relevant amount of variation in urinary parameters among pediatric patients who undergo 24-hour collections. While we recognize the inconvenience of performing a metabolic evaluations, we believe that two collections should be performed as our data suggest that basing treatment decisions off a single collection may lead to undertreatment of pediatric stone formers.
Source of Funding: None
PD12-11 24-HOUR URINE CALCIUM OXALATE SUPERSATURATION RISK CORRELATES WITH CT VOLUMETRIC CALCIUM OXALATE STONE GROWTH
Stanislav Yuzhakov*, Shavano Steadman, Brandon Otto, Vincent Bird, Benjamin Canales, Gainesville, FL
INTRODUCTION AND OBJECTIVES:
In vitro studies have shown that calcium oxalate supersaturation (CaOX SS) principally drives CaOX stone formation and growth. As this has not been previously validated in humans, the objective of this study was to investigate the link between 24-hour urine CaOX SS and "in vivo" CT stone growth.
METHODS: From a database of 368 patients with >70% CaOX stone composition, we identified 72 individuals who, prior to stone intervention, obtained at least two separate CT scans and at least one 24-hour urine collection between the CT studies. In addition to demographic and laboratory data, two reviewers, blinded to each other 0 s findings, calculated bilateral 3D kidney stone volume using an ROI Pen Tool (Visage 7Ò Platform) on all image series. When measurements differed by >10%, a third reviewer served as an arbitrator. The difference between first and second CT was divided by
